Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease ( IgG4-RD ) expected around ...
Here's Why Shares in Theravance Biopharma Exploded Today
The company is making excellent progress on all its strategic goals.
Cytokinetics ( CYTK ) Q3 2025 Earnings Transcript
Image source: The Motley Fool.Wednesday, Nov. 5, 2025 at 4:30 p.m. ETPresident & Chief Executive Officer - Robert I. BlumContinue reading ...
Revolution Medicines ( RVMD ) Earnings Transcript
Image source: The Motley Fool.Wednesday, Nov. 5, 2025 at 4:30 p.m. ETChief Executive Officer - Mark A. GoldsmithContinue reading ...
Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update - Cytokinetics ( NASDAQ:CYTK )
Interactions with FDA Progressing Towards December 26, 2025 PDUFA Date for Aficamten; U.S. Commercial Launch Preparations on Track Ex-U.S. Regulatory Reviews of Aficamten Ongoing in China and E.U. ~$1.25 Billion in Cash, Cash Equivalents and Investments as of September 30, 2025
Royalty Pharma ( RPRX ) Beats Q3 Earnings and Revenue Estimates
Royalty Pharma (RPRX) delivered earnings and revenue surprises of +5.41% and +1.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nuvation Bio ( NUVB ) Q3 2025 Earnings Transcript
Image source: The Motley Fool.Monday, Nov. 3, 2025, at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences
NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it has acquired a royalty interest in Alnylam's AMVUTTRA from funds managed by Blackstone Life Sciences ( "Blackstone" ) for $310 million.
Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( NASDAQ:RPRX ) today announced that it has acquired a royalty interest in Alnylam's AMVUTTRA from funds managed by Blackstone Life Sciences ( "Blackstone" ) for $310 million.
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
Agios today announced financial results and updates for the third quarter ended September 30, 2025.
Agios Reports Third Quarter 2025 Financial Results and Provides Business Update
$12.9 million in third quarter PYRUKYND® ( mitapivat ) net revenues PDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025 CHMP adopted positive opinion for PYRUKYND in thalassemia; EC decision expected by early 2026
Royalty Pharma ( RPRX ) Earnings Expected to Grow: Should You Buy?
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Balancing Innovation and Income: A2 Fund Shares 2026 Market Outlook Following 75% YTD Fund Growth
WILMINGTON, Del., Oct. 28, 2025 /PRNewswire/ -- A2 Management, the investment adviser behind the A2 Growth Opportunities Fund, today released its 2026 market outlook, highlighting strategies that balance innovation-driven growth with consistent monthly income.
Praxis Precision Medicines ( PRAX ) Surges 183.7%: Is This an Indication of Further Gains?
Praxis Precision Medicines (PRAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Royalty Pharma Declares Fourth Quarter 2025 Dividend
NEW YORK, Oct. 17, 2025 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc ( Nasdaq: RPRX ) has approved the payment of a dividend for the fourth quarter of 2025 of $0.22 per Class A ordinary share.
Royalty Pharma Declares Fourth Quarter 2025 Dividend - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, Oct. 17, 2025 ( GLOBE NEWSWIRE ) -- The board of directors of Royalty Pharma plc ( NASDAQ:RPRX ) has approved the payment of a dividend for the fourth quarter of 2025 of $0.22 per Class A ordinary share.
Kailera Therapeutics Announces $600 Million Series B Financing to Further Advance Pipeline of Next-Generation Therapies for the Treatment of Obesity
- Financing led by new investor Bain Capital Private Equity with participation from new and existing investors to support continued development of a differentiated, late-stage portfolio of obesity treatments -
Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025
NEW YORK, Oct. 09, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at ...
Zenas Biopharma Raises $120M For Global MS Drug Rights - Zenas BioPharma ( NASDAQ:ZBIO )
Zenas BioPharma Inc. ( NASDAQ:ZBIO ) and InnoCare Pharma Ltd. on Wednesday announced a license agreement granting Zenas global development and commercialization rights to orelabrutinib for multiple sclerosis and across all therapeutic areas other than oncology.
Will Royalty Pharma ( RPRX ) Beat Estimates Again in Its Next Earnings Report?
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
- Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton's Tyrosine Kinase ( BTK ) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of Multiple Sclerosis ( MS ...
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director
NEW YORK, Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director.
Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, Sept. 29, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( NASDAQ: RPRX ) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director.
Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit
Trump's 100% tariff on imported drugs jolts markets, slamming pharma giants and dragging ETFs like XPH, FTXH, IHE, and PPH lower.
Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum
NEW YORK, Sept. 19, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in a fireside chat at Bernstein's 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET.
Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, Sept. 19, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that it will participate in a fireside chat at Bernstein's 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET.
How Do Investors Really Feel About Royalty Pharma? - Royalty Pharma ( NASDAQ:RPRX )
Royalty Pharma's RPRX short interest as a percent of float has risen 18.13% since its last report. According to exchange reported data, there are now 16.62 million shares sold short, which is 3.91% of all regular shares that are available for trading.
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation - Royalty Pharma ( NASDAQ:RPRX )
On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensus Goal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upside potential from recognition for Royalty Pharma's platform value
Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation
NEW YORK, Sept. 11, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) will host an Investor Day in New York City today. Senior executives will provide an update on the company's plans to drive shareholder value creation through its unique business model and capabilities in the large ...
Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market
NEW YORK, Sept. 10, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced the release of a biopharma royalty market study conducted by Deloitte. The report, titled "Role of Royalties in Funding Biopharma Innovation," is the first of its kind and offers a comprehensive ...
Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
NEW YORK, Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET.
Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes
NEW YORK, Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following ( collectively, the "Notes" ...
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million - Royalty Pharma ( NASDAQ:RPRX ) , Zenas BioPharma ( NASDAQ:ZBIO )
Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease
Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million
NEW YORK and WALTHAM, Mass., Sept. 02, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) and Zenas BioPharma, Inc. ( Nasdaq: ZBIO ) today announced that Royalty Pharma will provide up to $300 million in funding in exchange for a royalty on sales of obexelimab.
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease ...
What's Going On With BeOne Medicines Stock Monday? - Royalty Pharma ( NASDAQ:RPRX ) , BeOne Medicines ( NASDAQ:ONC ) , Amgen ( NASDAQ:AMGN )
BeOne to sell Imdelltra royalties for $885 million upfront, plus $65 million option within a year. Royalty deal excludes China, with profit-sharing on sales above $1.5 billion annually. See the seasonal trading strategy that's beating the S&P 500 by 6X this year. Details here → BeOne Medicines ...
Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million
NEW YORK, Aug. 25, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that it has acquired a royalty interest in Amgen's Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager ( BiTE ) , from BeOne Medicines for $885 million upfront.
Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million - Royalty Pharma ( NASDAQ:RPRX )
Imdelltra is a first-in-class immunotherapy for the treatment of extensive-stage small cell lung cancer ( ES-SCLC ) marketed by Amgen Royalty Pharma to pay $885 million upfront; BeOne Medicines to retain a $65 million option to sell additional portion of its royalty
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors
NEW YORK, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 ...
Henry Fernandez Steps Down from Royalty Pharma's Board of Directors - Royalty Pharma ( NASDAQ:RPRX )
NEW YORK, Aug. 13, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc RPRX today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025.
Theravance Sales Jump 83 Percent
Theravance Biopharma ( NASDAQ:TBPH ) , a biopharmaceutical company focused on respiratory medicines and rare disease therapeutics, reported its Q2 2025 results on August 12, 2025. The company's revenue ( GAAP ) grew to $26.2 million, slightly ahead of analyst estimates at $25.93 million.
Here's How Much $1000 Invested In Royalty Pharma 15 Years Ago Would Be Worth Today - Royalty Pharma ( NASDAQ:RPRX )
Royalty Pharma RPRX has outperformed the market over the past 15 years by 36.41% on an annualized basis producing an average annual return of 48.86%. Currently, Royalty Pharma has a market capitalization of $15.45 billion.
Royalty Pharma ( RPRX ) Q2 Receipts Up 20%
Royalty Pharma Plc ( NASDAQ:RPRX ) , a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts-its closest revenue proxy-rose 11% to $672 million but landed just under the $672.99 million analyst ...
Royalty Pharma ( RPRX ) Tops Q2 Earnings and Revenue Estimates
Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.64% and +5.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Royalty Pharma ( RPRX ) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Evaluate the expected performance of Royalty Pharma (RPRX) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Agios Reports Second Quarter 2025 Financial Results and Provides Business Update
Agios Pharmaceuticals today announced financial results and updates for the second quarter ended June 30, 2025.
Royalty Pharma ( RPRX ) Earnings Expected to Grow: Should You Buy?
Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Invesco Biotechnology & Genome ETF ( PBE ) a Strong ETF Right Now?
Smart Beta ETF report for ...
